Skip to main content

Table 2 Results of logistic regression for site of first (s) of recurrence

From: Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study

  Univariate analysis
OR (95% CI)
P-value Multivariable analysis
OR (95% CI)
P-value
  HR-negative vs.
HR-positive
  HR-negative vs.
HR-positive
 
Local regional
vs. Distant
1.06 (0.71, 1.59) 0.772 1.15 (0.75, 1.76) 0.531
Brain vs. Other 1.75 (1.05, 2.93) 0.033 1.63 (0.95, 2.81) 0.079
Bone vs. Other 0.53 (0.34, 0.82) 0.005 0.53 (0.34, 0.83) 0.005
Lung vs. Other 1.24 (0.76, 2.03) 0.393 1.27 (0.77, 2.09) 0.353
Liver vs. Other 1.38 (0.86, 2.22) 0.188 1.44 (0.89, 2.35) 0.139
  1. Note: HR, Hormone receptor. Adjusting by age at diagnosis, stage and adjuvant trastuzumab.